CORE--VECTOR

核心--向量

• 批准号: 6575137
• 负责人: Saswati Chatterjee
• 金额: $ 34.71万
• 依托单位: CITY OF HOPE NATIONAL MEDICAL CENTER
• 依托单位国家: 美国
• 财政年份: 2002
• 资助国家: 美国
• 起止时间: 2002-04-01 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6575137
• 关键词: adeno associated virus group; biomedical facility; recombinant virus; transfection /expression vector

The primary responsibility of the Vector Core (Core B) is the resolution of administrative, fiscal, and scientific issues pertaining to recombinant vector production. The Specific Aims of the Vector Core are central to the overall success of this proposal, and include: 1. Production, purification, and characterization of research grade recombinant adeno-associated (AAV) vector stocks for research projects: a. listed in this proposal and, b. non-proposed related, peer reviewed, NIH funded projects focusing upon heart, lung or blood diseases. 2. Process developed of methods of production and purification of AAV vectors and assays for characterization. 3. cGMP manufacturing and QC release of rAAV vectors for use in preclinical studies. 4. Promotion of cohesive, continuing scientific interactions with all project investigators so that the latest technological advances in vector design or development can be implemented. It is anticipated the production of high titer, qualified stocks of recombinant adenovirus and rAAV vectors will expedite acquisition of preclinical gene transfer data. Furthermore, use of cells and virus or vector stocks that are free of mycoplasma, helper virus (adenovirus) and particularly wild type AAV, will remove confounding variables which have plagued interpretation of several gene transfer studies. Finally, the Vector Core is not envisioned to be a static entity, but will interact with investigators and fully participate in the implementation of the latest technologic advances to improve gene transfer.

载体核心（核心B）的主要职责是解决与重组载体生产相关的行政、财政和科学问题。矢量核心的具体目标是这个建议的整体成功的核心，包括：1。用于研究项目的研究级重组腺相关（AAV）载体储备物的产生、纯化和表征：a.本提案中列出的，以及，B.非建议相关，同行评审，NIH资助的项目，重点是心脏，肺或血液疾病。2. AAV载体的生产和纯化方法以及表征测定的开发过程。3.用于临床前研究的rAAV载体的cGMP制造和QC放行。4.促进与所有项目调查人员的连贯、持续的科学互动，以便能够实施病媒设计或开发方面的最新技术进步。预期重组腺病毒和rAAV载体的高滴度、合格原液的生产将加快临床前基因转移数据的获取。此外，使用不含支原体、辅助病毒（腺病毒）和特别是野生型AAV的细胞和病毒或载体储液将去除困扰若干基因转移研究的解释的混杂变量。最后，载体核心并不是一个静态的实体，而是与研究人员互动，并充分参与最新技术进步的实施，以改善基因转移。